U.S. Stem Cell, Inc.

Equities

USRM

US90350U1007

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:46:59 2024-04-24 pm EDT			5-day change	1st Jan Change
0.0001 ^USD	-.--%		-.--%	-.--%

2023	U.S. Stem Cell, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
2023	U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt	CI

U.S. Stem Cell, Inc. Announces Management Changes

March 09, 2022 at 09:01 am EST

U.S. Stem Cell, Inc. announced that Mark Borman has been appointed as Chairman of the Board of Directors and William P. Murphy, Jr., M.D. has been bestowed with the title of Chairman Emeritus, effective March 4, 2022. Mr. Borman has served as a member of the Company's Board of Directors since May 2009. He is a seasoned financial officer with more than 30 years of broad-based financial and investor relations experience.

Mr. Borman brings small-company entrepreneurial passion and larger-company disciplines. In addition to the valuable experience he gained working with entrepreneurs and their startups from 2009 to present, Mr. Borman has experience with global, NASDAQ- and NYSE-listed companies in various executive and financial roles. He is currently a board member with public and private technology companies and serves on advisory and non-profit boards.

Latest news about U.S. Stem Cell, Inc.

U.S. Stem Cell, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-14	CI
U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt	23-04-13	CI
U.S. Stem Cell, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
U.S. Stem Cell, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-23	CI
U.S. Stem Cell, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-31	CI
U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt	22-03-30	CI
U.S. Stem Cell, Inc. Announces Management Changes	22-03-09	CI
U.S. Stem Cell, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-09	CI
U.S. Stem Cell, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-12	CI
U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt	21-07-15	CI
U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt	21-07-15	CI
U.S. Stem Cell, Inc.'s Equity Buyback announced on January 16, 2015, has expired.	20-12-30	CI
U.S. Stem Cell, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-06	CI
Tranche Update on U.S. Stem Cell, Inc.'s Equity Buyback Plan announced on January 16, 2015.	19-11-06	CI
U.S. Stem Cell, Inc. Announces Resignation of Kristin Comella as a Member of the Board of Directors and Her Position as Chief Scientific Officer	19-09-06	CI
U.S. Stem Cell, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-07	CI
Tranche Update on U.S. Stem Cell, Inc.'s Equity Buyback Plan announced on January 16, 2015.	19-08-07	CI
U.S. Stem Cell, Inc. Announces Earnings Results for the First Ended March 31, 2019	19-05-07	CI
Tranche Update on U.S. Stem Cell, Inc.'s Equity Buyback Plan announced on January 16, 2015.	19-05-07	CI
U.S. Stem Cell, Inc. Reports Earnings Results for the Fourth Quarter and Year Ended December 31, 2018	19-03-13	CI
Tranche Update on U.S. Stem Cell, Inc.'s Equity Buyback Plan announced on January 16, 2015.	19-03-13	CI
U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt	19-03-12	CI
U.S. Stem Cell, Inc. Announces Revenue Results for the Quarter and Financial Results for the Nine Months Ended September 30, 2018	18-11-07	CI
Tranche Update on U.S. Stem Cell, Inc.'s Equity Buyback Plan announced on January 16, 2015.	18-11-07	CI
U.S. Stem Cell, Inc. Appoints Phil Posa as Senior Vice President of U.S. & International Sales	18-09-11	CI

Chart U.S. Stem Cell, Inc.

Duration

Period

More charts

Company Profile

U.S. Stem Cell, Inc. is a biotechnology company. The Company is focused on the discovery, development and subject to regulatory approval and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. The Company's product candidates are MyoCell, MyoCell SDF-1 and Adipocell. MyoCell and MyoCell SDF-1 product candidates are clinical therapies designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. MyoCell SDF-1 is similar to MyoCell except that the myoblast cells to be injected for use in MyoCell SDF-1 will be modified prior to injection by an adenovirus vector or non-viral vector. Adipocell product candidate is a cell therapy kit with multiple possible treatment applications using autologous adipose cells. It is also investigating the use of adipose cells in a variety of clinical applications.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
U.S. STEM CELL, INC.	-.--%	66.15K
VERTEX PHARMACEUTICALS INCORPORATED	-1.17%	104B
REGENERON PHARMACEUTICALS, INC.	+2.87%	97.47B
ARGENX SE	+2.13%	22.25B
BIONTECH SE	-14.77%	21.68B
GENMAB A/S	-8.79%	18.2B
WUXI APPTEC CO., LTD.	-39.98%	17.02B
BEIGENE, LTD.	-13.21%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+8.55%	14.39B
SAREPTA THERAPEUTICS, INC.	+35.75%	12.37B

Bio Therapeutic Drugs